Search results
Showing 991 to 1005 of 1362 results for social care
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
CG173/4 Question What are the key factors, including additional care and support, that influence participation* and quality of life in...
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued Reference number: GID-TA10416
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented
In development Reference number: GID-TA10745 Expected publication date: 17 July 2024
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
Discontinued Reference number: GID-MT563
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]
Discontinued Reference number: GID-TA10047
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued Reference number: GID-TA10321
Discontinued Reference number: GID-TA10512
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244